Why choose Mtech Access for your HTA submission?
- We have a very experienced team who have collectively supported 170+ HTA submissions throughout their careers
- We are fully aware of all requirements for HTA submission with NICE, Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG) and the National Centre for Pharmacoeconomics (NCPE) Ireland
- We have long-term relationships with several ex-NICE committee members and with Andrew Walker from the SMC, to draw advice from, validate models or attend mock committee meetings, if needed
- We confirm the principles and assumptions behind our submissions with relevant payers, clinicians and other stakeholders from our broad global network
- In the UK, we have close relationships with over 80 contracted associates working in the NHS, who work directly with us on NICE and SMC submissions to help us ensure the evidence submitted is valid and reflects the patient pathway
- We have the in-house capability to support every element of your submission or to supplement your teams’ capability where needed
- This includes an in-house medical writing team, trained specifically in market access
- Along with in-house health economists and systematic literature review specialists and statisticians
To discuss your HTA Support needs with our experts, get in touch using the form below.
What is a Health Technology Assessment?
A Health Technology Assessment (HTA) systematically evaluates the properties and effects of a new drug, medical device, or other medical technology to assess whether these effects drive sufficient benefit to patients and wider society, relative to their cost.
The HTA submission dossier is typically submitted to a national body, such as NICE in England or SMC in Scotland, who assess the product’s clinical and economic value relative to current clinical practice.
The HTA body determines where a product is deemed to provide sufficient incremental value at an acceptable price to justify its use by the health service.
In many key markets, gaining approval by national reimbursement, pricing, or HTA agencies is critical to the commercial success of a new product launch.
HTA is the bridge between evidence and policy-making, providing a range of stakeholders with evidence-based information to guide decisions around the efficient allocation of resources.
Those that achieve a successful HTA submission overcome one of the most significant hurdles in the market access journey.
We offer a full HTA service delivered in-house by our highly experienced team of market access writers, health economists, literature review analysts, medical statisticians, and consultants.
This one-team approach delivers quality, consistency, and efficiency for our clients.
Health Technology Assessment (HTA) Support
Discover how we can help you overcome one of the most significant hurdles in market access… the HTA submission.
Which health technologies are assessed?
- Pharmaceuticals
- Devices
- Diagnostic tests
- Procedures
- Technologies for orphan/ultra orphan/end-of life conditions
- Emerging: Apps/digital technologies
Support for each step of the Health Technology Assessment journey
We offer a full service, from strategy through to evidence generation, dossier writing, and post-submission support. We believe that providing the full HTA service delivers quality, consistency and efficiency benefits for our clients.
We are leaders in:
- Submission strategy
- Review and critique of materials for HTA suitability
- Cost-effectiveness and budget impact modelling
- Systematic literature review and network meta-analysis
- HTA submission and reimbursement support dossier writing
- Project management
- Post-submission support
- Mock committee meetings
- The full HTA journey from strategy to implementation
NICE META Tool – Support for Medtech Innovators
As a certified NICE META Tool facilitating organisation, we help Medtech and Digital Health companies to identify gaps in their product development and evidence generation plans. Work with our experts to understand the evidence requirements of key healthcare decision makers, develop a compelling, evidence-rich value proposition, and prepare for commercial launch.
Articles related to Health Technology Assessment
EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?…
AMCP dossier planning for US market access and reimbursement
What is an AMCP dossier and how are they used in US market access? Drawing on their extensive experience compiling AMCP dossiers, here, our global market access experts explain when, why and how…
From SMC Assessor to HTA Consultant
Maria Dimitrova shares her career journey from public sector roles working with the SMC and SHTC to joining Mtech Access as a Consultant supporting our Pharma and Medtech clients with HTA submissions…